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Drug-induced changes in renal hippurate clearance as a measure
of renal blood flow
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Drug-induced changes in renal hippurate clearance as a measure of
renal blood flow. We studied the accuracy of the plasma 1311-hippurate
clearance technique to monitor drug-induced changes in renal blood flow
(RBF) by comparing it to a flow probe technique in six conscious,
chronically instrumented dogs. Placebo caused no change in RBF, either
established by hippurate clearance (ERPF5) or by renal blood flow probe
(RBFproh,,). Enalaprilate induced a rise in ERPFhIP and RBFPrObC (+26
5 and 44 12%), as did dopamine (+16 4 and +33 5%). Intravenous
infusion of norepinephrine induced a rise in ERPFhIP (+2 6%, NS) and
in RBFprob,, (+18 3%), as did nitroprusside (+14 4% and +13 6%,
NS). Indomethacin induced a fall in ERPFhP (—8 2%) and in RBFprObc
(—7 3%, NS), as did angiotensin II (—19 1 and —26 3%). Renal
hippurate extraction (EhI) was affected by enalaprilate, dopamine, and
angiotensin II (—5 2, —7 1, and +5 2%, respectively). Hematocrit
(Hct) was affected by dopamine, norepinephrine, and nitroprusside (+2
1, +6 1, and —6 2%, respectively). Drug-induced changes in ERPF5Ip
correlated well with changes in RBFPr,b (r = 0.902, P < 0.01). Changes
in E1 did not independently affect this relation, whereas changes in Hct
did: RBF(% of baseline) = 1.529 X IIERPFSiP(% of baseline) + 1.296
X zHct(% of baseline). These data indicate that drug-induced changes in
plasma hippurate clearance can, even when changes in renal hippurate
extraction are unknown, be used as a reliable indicator of changes in renal
blood flow if changes in hematocrit are taken into account.
The renal clearance of exogenously infused hippurate has
frequently been used since the fifties [1] as a means to establish
renal blood flow (RBF) both in the clinical and the laboratory
setting. This application is based on the presumption that plasma
passing the kidney is nearly completely and constantly cleared of
hippurate. Some hippurate, however, appears to escape renal
clearance, so that renal hippurate extraction (EhIP) is never 100%
[1]. Thus, renal hippurate clearance can only be used as an
absolute measure of RBF when corrected for EhIP. In practice this
is not often done since EhP determination requires an invasive
catheterization of the renal vein. Despite this, acute or even
chronic changes in RBF induced by drug or other interventions
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may still be accurately measured using renal hippurate clearance
without knowing Eh1P, presuming that the intervention does not
change EhIP. Yet, vasoactive substances are reported to affect EhIP
[2—41. In addition, changes in hematocrit may occur affecting the
relation between RBF and hippurate (plasma) clearance. Thus,
(drug)-induced changes in renal hippurate clearance are com-
monly considered to be an imprecise indicator even of changes in
RBF [5—7]. To our knowledge, however, no studies have directly
compared the clearance technique with the gold standard, the
renal artery blood flow probe, in measuring drug-induced changes
in RBF and evaluated the impact of changes in EhIP or hematocrit
on the measurement.
In the present study we therefore compared changes in directly
measured RBF with changes in plasma hippurate clearance with
and without correction for EhIP and/or hematocrit in chronically
instrumented conscious dogs. These changes were induced by
different drugs and hormones which are of clinical importance
(enalaprilate, dopamine, norepinephrine, nitroprusside, indo-
methacin, and angiotensin II).
Methods
Six male mongrel dogs (25 to 33 kg body wt) were trained to
become accustomed to the experimental situation and were kept
on a salt restricted diet of less than I g of salt per day (H/D
Prescription Diet, Hill's Pet Products, Topeka, KS, USA).
Instrumentation
Instrumentation was performed in two steps under general
anaesthesia (induction with thiopental, maintenance anaesthesia
with nitrous oxide and isoflurane). First, the left renal artery was
exposed retroperitoneally through a flank incision and dissected
from surrounding tissue. Subsequently, a transit-time flow probe
(Transonic Systems, Ithaca, NY, USA) of appropriate size was
placed around the renal artery. Furthermore, Tygon catheters
(Norton, Akron, OH, USA; o.d. 1.8 mm, i.d. 1.0 mm) were placed
in the descending aorta and the right atrium through the omocer-
vical artery and vein, respectively [8]. Second, after a period of
about two weeks recovery, the left renal vein was exposed through
a midline incision and the spermatic vein was ligated to prevent
sampling of non-renal blood. A heparin-coated Tygon catheter
was placed in the renal vein through and fixed onto the inferior
caval vein. All leads were tunnelled subcutaneously to a location
high on the back of the animal, and covered by a jacket. The
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Fig. 1. Convlation between left renal blood flow measured by flow probe
(RBFP,,h) and established by renal venous outflow (RBF,,,) in two dogs (•
and 0). The solid line indicates the line of identity.
position of the renal vein catheter was verified before each
experiment by oxygen saturation measurement [9]. All catheters
were kept patent by refilling them daily with a fresh heparin
solution (2000 IE/ml).
Flow probes were precalibrated by the producer. In two dogs
under general anaesthesia calibration was verified in vivo after the
final experiment. This, by comparing flow probe values with renal
venous outflow measurements, Changes in renal blood flow were
induced by bleeding: One flow probe constantly overestimated (22
7%) whereas the other flow probe slightly underestimated (—9
5%) renal blood flow. Furthermore, calibration curves were
perfectly linear (r = 0.98 and >0.99; Fig. 1). By intra-arterially
injected angiotensin II (5 to 10 j.tg) it was verified in vivo that no
drifting of zero level occurred [10].
Experimental design
After completion of the instrumentation the animal was al-
lowed to recover for a least one week. The acute effects of
placebo, enalaprilate (ACEi), dopamine (DOP), norepinephrine
(NE), nitroprusside (NIP), indomethacin (IND), and angiotensin
II (Ang II) were studied on subsequent experimental days in a
randomized order. Placebo, ACEi (10 mg enalaprilate i.v.) and
IND (1 mg kg' Indocid® P.D.A. i.v.; a gift of MSD, Haarlem,
The Netherlands) were given in a single dosage, whereas DOP,
NE, NIP, and Ang II were continuously infused (15 ml hr1 i.v.)
at a dose titrated to a 10 to 30% change in mean arterial pressure
and renal blood flow. Drugs were dissolved in 5% glucose. To
prevent drug interaction or carry-over, the drugs were studied
during at least one week intervals.
Before the experimental day dogs had free access to water, but
they were deprived of food for at least eight hours. During the
experiment the trained dog was conscious and hanging quietly in
a hammock. To provide adequate urine production 5% glucose
was infused continuously at a rate of 250 ml hr'. Urine was
collected by bladder catheterization. After a priming dose, 1311
hippurate was infused at a rate of 12 ml hr1 according to the
method described by Donker et al [11]. After a stabilization
period of two hours, six half-hour renal clearance periods were
performed: three baseline measurements followed by three drug
or placebo measurements (starting 1 hour from administration).
To measure renal hippurate extraction, arterial and renal venous
blood samples were always drawn in the same order within three
minutes of each other. Blood samples were immediately centri-
fuged at 4°C (480 g) and plasma was removed immediately to
prevent diffusion of hippurate from the red cells into plasma.
Before the baseline and after the experimental period arterial
blood samples were drawn to establish hematocrit (Hct). During
the baseline as well as during the experimental period mean
arterial pressure (MAP: Disposable Pressure Transducer, Cobe®
Laboratories) and left renal blood flow (RBFprobe: renal artery
probe) were continuously registered.
Data analysis
Renal vascular resistance was calculated as MAP divided by
RBFprobe.
The extraction ratio of hippurate was calculated as the differ-
ence between arterial (AhP) and renal venous 1311-hippurate
concentration (Vh,) divided by Ah)P:
Eh1 = (A — VP)/AhP
Renal clearance of '311-hippurate was calculated according the
following formula:
ERPFh1(U) = unneblP X urine flow rate/A
Plasma clearance of hippurate was calculated as follows:
ERPF(I) = infusate X infusion rate/A
Renal blood flow (RBFhIP) was subsequently calculated as:
RBFhP = ERPFhP/{EIJP x (1 — Hct)]
The means of the three clearance periods before and after drug or
placebo administration were used as the respective baseline
experimental values. Values are expressed as mean SEM.
Statistical analysis was performed with the commercially available
software program Instat (GraphPad Software, San Diego, CA,
USA). Differences between baseline and experimental values
during placebo were tested by the Student's paired t-test. Drug-
induced changes were expressed as percentage change from
baseline, and subsequently tested by comparing them with the
placebo values by the paired t-test. The relation between changes
in ERPFhIP, EhiP, and Hct and changes in RBFPrObC was tested by
multiple variable regression analysis. Differences and correlations
were considered significant at a level of 5%.
Results
Baseline values
Table 1 shows the baseline values of all parameters established
during the experimental days with placebo (N = 6), ACEi (N =
5), dopamine (N = 5), norepinephrine (N = 5), nitroprusside (N
= 6), indomethacin (N = 6), and angiotensin II (N = 6). No
significant differences were observed, although baseline values
varied slightly between the experimental days. Furthermore,
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Table 1. Baseline values of mean arterial pressure (MAP), renal vascular resistance (RVR), left renal blood flow (RBFprObe), plasma [ERPFhIP (I)]
and renal hippurate clearance [ERPFhP (U)I, renal hippurate extraction (Eh,P), haematocrit (Hct), and renal blood flow as established by plasma
hippurate clearance (RBFhIP)
MAP
mm Hg
RVR
mm Hg/mm/mi
RBFprOb ERPFhIP (I) ERPFhIP (U)
EhI
Hct
%
RBFhP
mI/mmmi/mm
Plac 113 5 0.460 0.023 246 8 305 27 306 26 0.77 0.02 39 3 618 43
ACEi 109 6 0.449 0.042 248 16 294 34 291 34 0.77 0.02 42 1 655 59
DOP 113 5 0.480 0.046 241 21 291 20 297 28 0.75 0.02 40 3 639 27
NE 109 6 0.505 0.075 225 24 294 33 297 33 0.77 0.02 39 1 646 80
NIP 109 6 0.415 0.048 276 29 322 35 316 36 0.78 0.02 40 2 693 67
IND 111 5 0.446 0.051 265 30 325 24 341 27 0.75 0.03 38 2 701 46
Ang II 109 4 0.416 0.044 277 30 322 32 314 34 0.74 0.02 40 2 726 62
Values shown during placebo (Plac), enalaprilate (ACEi), dopamine (DOP), norepinephrine (NE), nitroprusside (NIP), indomethacin (IND), and
angiotensin II (Ang II) experiments.
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Fig. 2. Individual values of left renal blood flow measured by flow probe (RBFP,.c,b), plasma hippurate clearance (ERPFh,I,), and renal hippurate e.rtraction
ratio (E1,q,), before and after administration of placebo, enalaprilate (ACEi), dopamine (DOP), norepmnephrine (NE), nitroprusside (NIP), indomethacin
(IND), or angiotensin II (Ang II) (*P < 0.05 vs. baseline, #P < 0.05 vs. placebo).
Drug-induced changesbaseline values of ERPFhIP(I) and ERPFhiP(U) were comparable.
This indicates that at steady state the appearance rate of hippu-
rate in the plasma equals the appearance rate in the urine, and
that ERPFhP(I) can be substituted by ERPFhIP(U). Since
ERPFhP(I) is not subject to errors introduced by incomplete
urine collection or dead-space, this entity was used to establish
drug-induced changes in renal hippurate clearance.
Figure 2 shows the individualvalues of RBFPrOBe, ERPFhIP, and
EhIP on the different experimental days, whereas in Figure 3 the
average placebo corrected changes are shown.
Placebo. Placebo infusion did not induce significant changes in
MAP and RVR (+2 1 and +3 2%). As can be seen in Figure
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Fig. 3. Placebo corrected percentile changes (mean SEM) in (A) left renal
blood flow measured by flow probe (RB! ,h), (B) plasma hippurate
clearance (ERPFhiP), and (C) renal hzpurate extraction ratio (E,,1) induced
by enalaprilate (ACEi), dopamine (DOP), norepinephrine (NE), nitropms-
side (NIP), indomethacin (IND), and angiotensin II (Ang II) (*P < 0.05 vs.
placebo).
2, RBFprObC and ERPFhIP also did not change significantly (—1
1 and
—6 2%). EhI, however, fell significantly during the course
of the experiments (—7 1%). Hct was not affected by placebo
infusion (—3 2%), as was true for RBFhIP (—0 2%).
Drug-induced changes as discussed in the following paragraphs
are corrected for these placebo effects.
Enalaprilate. In response to ACEi (10 mg) both MAP and RVR
fell (—14 1 and —40 6%). RBFPrObe and ERPFhP both rose,
whereas EhIP fell (Fig. 3). ACEi did not affect Hct (+1 3%), but
induced a rise in RBFhP (+35 9%).
Dopamine. In response to infusion of 0.29 0.03 mg kg
hr dopamine, MAP remained unchanged (—2 2%), whereas
RVR fell (—27 4%). Both RBFprohe and ERPFhIP rose and EhIP
fell (Fig. 3). Furthermore, dopamine infusion induced a significant
rise in Hct and in RBFhIP (+2 1 and +28 6%).
Norepinephrine. Infusion of 0.02 mg kg1 - hr 1 resulted in a
significant rise of MAP (+17 2%), whereas, intriguingly, RVR
remained unchanged (—1 2%). RBFPrObC rose, while ERPFhIP
and EhI remained stable (Fig. 3). Hct rose (+6 1%), whereas
RBFhIP rose non-significantly (+6 4%).
Nitroprusside. Nitroprusside was given at a mean dosage of 0.29
0.03 mg kg1 -hr'. This resulted in a fall in MAP as well as
RVR (—23 2 and —31 6%). RBFprobe was not significantly
affected, whereas ERPFhIP rose significantly (Fig. 3). Nitroprus-
side infusion did not affect EhI (Fig. 3), but induced a significant
fall in Hct (—6 2%). In contrast with ERPFhIP, RBFhiP did not
change significantly (+11 5%).
Indomethacin. In response to indomethacin (1 mg kg') MAP
and RVR remained unchanged (—6 4 and +2 5%). Acute
inhibition of prostaglandin synthesis, however, resulted in a fall,
non-significantly, in RBFprobe and, significantly, in ERPFhIP (Fig.
3). EhIP did not change (Fig. 3), as was true for Hct (—1 3%).
RBFhIP fell (—8 2%).
Angiotensin II. Infusion of 0.51 0.08 xg kg1 hr1
angiotensin II resulted in a rise of MAP (+14 3%), as well as
RVR (+56 6%). Both RBFpr,)hC and ERPFhIP fell, but EhIP rose
(Fig. 3). Hct was not affected by infusion of angiotensin II (+0
2%). RBFhIP, however, fell (—24 2%).
Relation between changes in RBFP,Oh and changes in plasma
hippurate clearance
Linear regression analysis showed that drug-induced changes in
ERPFhP correlated well with changes in RBFPtOhe (r = 0.902, P <
0.01; Fig. 4A). The slope, however, was significantly different from
the line of identity (0.562, 95% CI 0.463 to 0.661), indicating that
changes, either a rise or fall, in ERPFhP were less pronounced in
comparison with changes in RBFPrObC. Stepwise correction of
changes in ERPFhIP for Hct (Fig. 4B), for EhIP (Fig. 4C), or for
both parameters (Fig. 4D) improved the relation such that,
indeed, changes in RBFhiP were nearly identical with changes in
RBFPrObC (slope 0.817, 95% CI 0.731 to 0.903; r = 0.961, P <
0.01). Interestingly, changes in EhIP correlated inversely with
changes in RBFPTOhe (r = —0.789, P < 0.01), whereas changes in
Hct did not (r = 0.204, P > 0.05). Multiple regression analysis
showed that changes in EhP did not independently affect the
relation between drug-induced changes in ERPFhIP and changes
in RBFPr0bc. This indicates that in estimating changes in RBF by
means of the hippurate clearance technique, EhIP can be substi-
tuted by a constant regression coefficient of ERPFhIP. This
observation contrasts with the finding that changes in Hct did
independently contribute to the relation between changes in
ERPFhIP and changes in RBFProbe (P < 0.01). This implies that in
using changes in hippurate clearance as a measure of changes in
RBF, a correction for changes in Hct needs to be performed.
Thus, the present data indicate that for practical purposes changes
in RBF can be calculated (RBFCaIC) without knowledge of EhIP,
with the following formula:
RBF(% of baseline) = 1.529 X zERPF(% of baseline) + 1.296
x Hct(% of baseline), as shown in Figure 5 (r = 0.939, P < 0.01).
Discussion
We compared drug-induced changes in renal blood flow mea-
sured by renal blood flow probe (RBFPr0bc) and by plasma
hippurate clearance (ERPFhIP). Changes in RBFPrOhe and
ERPFhIP correlated well (r = 0.902, P < 0.01), although changes
in ERPFhIP were less pronounced in comparison with changes in
RBFPrOhe. Correction of changes in ERPFhIP for renal hippurate
extraction (EhI) and hematocrit (Hct) improved the relation with
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changes in RBFprobe. However, since changes in EhIP were
inversely related to changes in RBFPrObC, only changes in Hct
affected the relation between changes in ERPFhP and RBFPrObe
independently. This indicates that for practical purposes drug-
induced changes in ERPFhIP, corrected for Hct, are a good means
to establish changes in renal blood flow.
An objection that might be raised against our study is the fact
that RBFprobe was established for one kidney only. Since drug-
induced changes in RBF are very likely to be the same in both
kidneys, relative changes in one kidney RBFPrObe can well be
compared with changes in plasma hippurate clearance. The
present data show that a good relation exists between the drug-
induced relative changes in ERPFhIP and relative changes in one
kidney RBFprobe. Drug-induced changes in ERPFhIP, however,
were less pronounced than those in RBFprObe. This is a phenom-
enon which, in agreement with others [6], can be largely overcome
by correcting ERPFhP for Eh and Hct. However, the present
data also indicate that EhIP does not independently affect the
relation between changes in ERPFhIP and changes in RBFprobe
and can thus be substituted by a simple correction factor. This
observation has an important clinical impact: the determination of
EhIP requires renal vein catheterization. Hct measurements, on
the other hand, are relatively simple to perform. Since changes in
this parameter independently affect the relation between changes
in ERPFhP and changes in RBFPrObe, changes in Hct must be
established to obtain adequate results. Thus, our data show that
Fig. 4. Correlations between dmg-induced
changes in plasma hippurate clearance and
changes in left renal blood flow measured by
renal a/Ic!)) probe (RBFP,,b). (A) Changes in
plasma hippurate clearance without Correction
(r = 0.902). (B) Changes in plasma hippurate
clearance corrected for Hct (r = 0.932). (C)
Changes in plasma hippurate clearance
corrected for Eh (r = 0.942). (D) Changes in
plasma hippurate clearance corrected for both
Hct and EhIP (r 0.961). Changes in response
to enalaprilate (0), dopamine (•),
norepinephrine (A), nitroprusside (A),
0 40 80 indomethacin (0), and angiotensin II (•). The
solid line indicates the line of identity, the
dotted line indicates the regression line.
without knowledge of EhIP, drug-induced changes in plasma
hippurate clearance corrected for changes in Hct are a good
means to establish changes in renal blood flow. In doing so it
should be kept in mind that the presented algorithm is based upon
the existence of a negative relation between changes in renal
blood flow and changes in In renal disease, such as renovas-
cular hypertension [3, 12], this relation may be disturbed and
therefore the computation is no longer valid.
How can we explain the observed changes in renal hippurate
extraction? In the present study EhP fell during placebo as well as
during ACEi and dopamine, whereas EhP rose in response to
angiotensin II. The findings on the changes induced by ACEi and
angiotensin II are comparable with previous findings on renal
extraction of paraaminohippurate and orthoiodohippurate [2, 3],
whereas the dopamine induced fall in EhI to our knowledge has
never been reported. Several factors have been proposed to affect
renal extraction of hippurate or its derivatives [13]. First, a
pronounced fall in glomerular filtration rate (GFR) might induce
a fall in EhIP [14]. Second, EhIP might fall due to inhibition of the
tubular transport mechanism by competition between drug and
hippurate for the organic anion transport mechanism [15—171.
Third, renal tracer extraction may be changed by alterations in
intrarenal blood flow distribution [2, 5, 18, 19]. Fourth, due to
changes in plasma transit time, EhP might change inversely with
changes in RBF [4, 5, 201. Lastly, it has been suggested that the
rate of renal tracer secretion is enhanced by an increase in sodium
C D
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Fig. 5. Correlation between drug-induced calculated changes in RBF
(RBF1), based upon changes in ERPF,J, and changes in Hct, and changes
in left renal blood flow measured by renal artely probe (RBF,.0b,.). Changes
in response to enalaprilate (0), dopamine (•), norepinephrine (A),
nitroprusside (h), indomethacin (Eli), and angiotensin II (•). The solid
line indicates the line of identity, the dotted line indicates the regression
line.
reabsorption rate [21, 22]. The observed fall in EhiP during
placebo cannot be attributed to changes in renal function since
RBF as well as RVR remained stable. Tubular hippurate secre-
tion, however, may have been inhibited by the glucose infusion
either directly by competition [7] or indirectly by a fall in sodium
reabsorption rate via extracellular volume expansion [22]. An-
other possibility is redistribution of renal blood flow in favor of
the medulla due to renal nerve stimulation [23]. Both explanations
are speculative. Changes in cortical transit time as a cause of
changes in EhIP appears a good overall explanation for the
drug-induced changes in EhI, since in the present data a clear
negative relation exists between changes in EhP and changes in
RBFPrObC. Based upon the present results, however, it cannot be
concluded what, if any, overall explanation is the correct one.
The hemodynamic effects of the studied vasoactive drugs
compare well with previous data both in dog and man despite
considerable differences in study design. As previously shown,
ACEi induced a fall in systemic blood pressure (MAP) and renal
vascular resistance (RVR), and a rise in RBF established either by
flow probe or by hippurate clearance [3, 24, 25]. The effects of
angiotensin II were exactly the opposite [26]. Dopamine did not
affect MAP, but induced a fall in RVR and a rise in RBF
independent of the technique used [27, 28]. In response to
nitroprusside both MAP and RVR fell, whereas RBF, measured
either way, did not change significantly [29, 301. The observation
that intravenously infused norepinephrine induced a rise in
RBFProhe without a change in RVR, however, contrasts with the
general opinion that norepinephrine induces a fall in RBF with an
increase in RVR [31]. The latter conclusion is based on studies
performed during anaesthesia and/or in which RBF was measured
by means of clearance techniques. Indeed, Anderson, Korner and
Selig showed, as we did, in conscious dogs using Doppler flow
probes, that intravenous infusion of norepinephrine induces a rise
in RBF [32]. They attributed this RBF increase to a reflex
mediated vasodilation, a mechanism which is likely to be inhibited
during anaesthesia [33]. Another interesting example of anaesthe-
sia/drug-effect interaction is the study of Swain et al [34] in dogs,
who showed that during anaesthesia indomethacin induced a fall
in RBF (probes), whereas during consciousness this fall was not
significant. In the present study, indomethacin indeed induced a
non-significant fall in RBFPrObC. Thus, the present data once more
stress that one should be careful when interpreting results from
experiments during anaesthesia.
In conclusion, the present data indicate that changes in plasma
hippurate clearance are a good means to establish drug-induced
relative changes in renal blood flow. A simple algorithm which
takes changes in hematocrit into account suffices for the conver-
sion of hippurate clearance data to changes in renal blood flow. If
the algorithm is used, knowledge of the actual renal hippurate
extraction is not needed. Since drug effects on plasma hippurate
clearance, renal hippurate extraction, and hematocrit reported
are comparable in dog and humans, extrapolation of the algo-
rithm to humans appears valid. Therefore, renal vein catheteriza-
tion to obtain renal hippurate extraction is unnecessary in this
setting.
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